New study describes the discovery of novel small molecule drug candidates that target α-synuclein and protect in #Parkinsons cellular models, first authored by Cantabio's CEO Dr Gergely Tóth in Nature's Scientific Reports: nature.com/articles/s4159…

Cantabio's CEO Dr Gergely Tóth to present novel findings on the company’s therapeutic programs on DJ-1 and Tau for #Parkinsons and #Alzheimers at AAT-AD/PD Focus Meeting 2020 #AATADPD in Vienna.

There is always challenge to fill up clinical trials for #Parkinsons. 85 percent of trials face delays and 30 percent never get off the ground because of a lack of volunteers, resulting in a dramatic slowdown in progress toward a cure. Please check out michaeljfox.org now!

An advice from michaeljfox.org on COVID-19 for #Parkinson’s patients. michaeljfox.org/news/ask-md-co…

Cantabio is presenting novel findings on its therapeutic programs targeting the DJ-1 and Tau proteins for #Parkinsons and #Alzheimers at the AAT-AD/PD Focus Meeting 2020 #AATADPD from April 2nd, 2020

michaeljfox.org/news/honoring-… A special day on April 11th, World Parkinson’s Day, Let's keep going until we find a cure!

FDA approves Tauvid™, the first novel PET imaging agent for the detection of tau protein tangles, an important pathological marker of tauopathies such as #Alzheimers and #Parkinsons, for aiding the diagnosis and progression of #Alzheimers. fda.gov/news-events/pr…

Recent publication in Annals of Neurology report #Parkinsons patient with previously unknown homozygous mutation in DJ-1 protein highlighting its importance in the on-set of #Parkinsons. onlinelibrary.wiley.com/doi/abs/10.100…

Cantabio receives grant from Michael J. Fox Foundation to develop new detection technologies for DJ-1 protein to create a novel much needed biomarker for the potential early diagnosis and tracking of the progression of #Parkinsons disease. accesswire.com/606377/Cantabi…

It is World Alzheimers's month! Cantabio is developing novel disease modifying therapeutics for #Alzheimers disease.

Cantabio Pharmaceuticals's CEO, Dr. Toth, is presenting novel findings on targeting the intrinsically disordered state of proteins as a therapeutic strategy against diseases such as #Alzheimers & #Parkinsons, at The Protein Misfolding Drug Discovery Summit on October 29, 2020.

Cantabio Pharmaceuticals's CEO, Dr. Toth, is presenting novel findings on therapeutic strategies targeting the DJ-1 protein misfolding linked to the onset of #Parkinsons disease at the Targeting Protein Misfolding Congress on March 15, 2021 kisacoresearch.com/events/targeti…

Editorial in Drug Discovery Today, by Cantabio's CEO Dr. Toth and colleagues at UCL UCL School of Pharmacy, argues that crowdfunding is a promising way to generate new capital for funding R&D for #Alzheimers and #Parkinsons. sciencedirect.com/science/articl…

Cantabio's drug discovery approach and therapeutic pipeline in #Alzheimers, #Parkinsons and #Diabetes is discussed by Dr. Toth in an interview at Careers in Discovery. anchor.fm/careers-in-dis…

Cantabio Pharmaceuticals's CEO, Dr. Toth, is presenting on the therapeutic targeting of the intrinsically disordered state of Tau and alpha-synuclein as a potential treatment approach for #Alzheimers & #Parkinsons at NeuroScience 2021. labroots.com/webinar/develo…

@Cantabio’s CEO, Gergely Toth, pitches the company in the finals of the 2021 ATECH Zhongguancun International Frontier Technology Innovation Competition in the Biomedicine category held in Beijing on September 27, 2021. globaltimes.cn/page/202109/12…

Cantabio awarded major grant from The Michael J. Fox Foundation to develop novel small-molecule aggregation inhibitors of the tau protein for the treatment of Parkinson’s disease accesswire.com/viewarticle.as…

Novel technologies developed by #Cantabio to quantifying various redox forms of the DJ-1 protein for early diagnosis of #Parkinsons disease is presented by the company’s CEO, Dr. Toth, at #BiomarkersUK conference in London on April 4, 2022. lnkd.in/ePkxbkX

Dr. Toth is presenting an overview and novel findings on Cantabio Pharmaceuticals's therapeutic strategies targeting the DJ-1 protein for the treatment of #Parkinsons disease at the Neuroscience Discovery Symposium on September 15, 2022

Cantabio Pharmaceuticals announces the award of a major grant from The Michael J. Fox Foundation for Parkinson’s Research for the Development of a Novel DJ-1 Protein Replacement Therapy for the Treatment of Parkinson’s Disease accesswire.com/viewarticle.as…